Establishment and application value of a novel prescription medication abuse monitoring model for psychiatric hospitals

ObjectiveTo construct a prescription medication abuse (PMA) monitoring model for psychiatric hospitals and to assess its applicability. MethodsA PMA monitoring working group was established to guide the formulation of a PMA monitoring system, which included three active real-time monitoring modes and one retrospective analysis monitoring mode. The effect of the established system was analyzed. ResultsIn 2021, 35 cases of effective PMA were reported, which was a significant increase compared to two cases identified through passive monitoring mode in the preceding year. Most of the reported cases were based on active real-time monitoring mode. Among them, 21 cases (60.00%) were identified during the diagnosis and treatment of medicine and nursing; 3 cases (8.57%) were reported based on drug concentration detection technology; and 5 cases (14.29%) were reported by the laboratory department during PMA screening. Besides, 6 cases (17.14%) were reported according to the retrospective analysis of the hospital information system. The majority of prescription medication abusers were adolescents under the age of 18 (12 cases, 34.29%). Overall, there were 27 cases of class II psychotropic prescription medications, accounting for 77.14%. ConclusionThe combined PMA monitoring model can effectively improve the quality of PMA monitoring and provide a basis for the supervision of higher-level regulatory authorities.

Automated summary

The study aims to establish a prescription medication abuse (PMA) monitoring model for psychiatric hospitals and assess its applicability. The established monitoring system resulted in a significant increase in the number of reported cases of PMA compared to the previous year. Most cases were identified through active real-time monitoring and involved adolescents. The combined monitoring model effectively improves the quality of PMA monitoring and provides a basis for higher-level regulatory authorities' supervision.